144 related articles for article (PubMed ID: 38757346)
1. Dual‑regulated oncolytic adenovirus carrying
Zhao T; Ye W; Zhang R; Zhu X; Shi Q; Xu X; Chen W; Xu L; Meng Y
Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38757346
[TBL] [Abstract][Full Text] [Related]
2. Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.
Xu Q; Liu Y; Wang S; Wang J; Liu L; Xu Y; Qin Y
BMC Cancer; 2022 Jun; 22(1):628. PubMed ID: 35672728
[TBL] [Abstract][Full Text] [Related]
3. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
4. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
5. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
Zhang W; Wu FX; Wang Q; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
[TBL] [Abstract][Full Text] [Related]
6. ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells.
Jung BK; Kim YJ; Hong J; Chang HG; Yoon AR; Yun CO
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806132
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
8. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
Fan Y; Wang L; Han X; Liu X; Ma H
Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
[TBL] [Abstract][Full Text] [Related]
9. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
10. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.
Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y
J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
Fang L; Cheng Q; Li W; Liu J; Li L; Xu K; Zheng J
Virus Res; 2014 Mar; 181():61-71. PubMed ID: 24463503
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effect of a dual cancer-specific recombinant adenovirus on ovarian cancer cells.
Cui Y; Li Y; Li S; Li W; Zhu Y; Wang J; Liu X; Yue Y; Jin N; Li X
Exp Cell Res; 2020 Nov; 396(1):112185. PubMed ID: 32828827
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
14. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
15. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.
Rein DT; Volkmer A; Bauerschmitz G; Beyer IM; Janni W; Fleisch MC; Welter AK; Bauerschlag D; Schöndorf T; Breidenbach M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):603-10. PubMed ID: 22209976
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
17. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
18. RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion.
Xu Y; Chu L; Yuan S; Yang Y; Yang Y; Xu B; Zhang K; Liu XY; Wang R; Fang L; Chen Z; Liang Z
Cell Death Dis; 2017 Jun; 8(6):e2835. PubMed ID: 28569774
[TBL] [Abstract][Full Text] [Related]
19. LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions.
Ju X; Yu H; Liang D; Jiang T; Liu Y; Chen L; Dong Q; Liu X
Biomed Pharmacother; 2018 Jun; 102():549-554. PubMed ID: 29597088
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
